| Dr Barry Stephen Lachman, MD, MPH | |
|
2777 N Stemmons Fwy Ste 1750, Dallas, TX 75207-2272 | |
| (214) 266-2104 | |
| (214) 266-2150 |
| Full Name | Dr Barry Stephen Lachman |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 2777 N Stemmons Fwy Ste 1750, Dallas, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124319017 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | L6093 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barry Stephen Lachman, MD, MPH 2777 N Stemmons Fwy Ste 1750, Dallas, TX 75207-2272 Ph: (214) 266-2104 | Dr Barry Stephen Lachman, MD, MPH 2777 N Stemmons Fwy Ste 1750, Dallas, TX 75207-2272 Ph: (214) 266-2104 |
News Archive
Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.
Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has just launched Oncology Performance Edge, a new strategic research service that helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources.
Medical crowdsourcing is like the ultimate consult service. A question arises, it is asked on the forum, and you can get answers from multiple specialties within minutes. It is harnessing the brightest minds in one place and using that power to do what we enjoy doing most – helping people.
As antiretroviral drugs that treat HIV have become more commonplace, the incidence of Kaposi's sarcoma, a type of cancer linked to AIDS, has decreased in the United States.
Threshold Pharmaceuticals, Inc. today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.
› Verified 2 days ago
Dr. Jyothsna Gattineni, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3438 | |
Ruth Osei Fordjour, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12221 Merit Dr, Suite 1500, Dallas, TX 75251 Phone: 214-957-4754 | |
Dr. Alecia Curlene Nero, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-4180 | |
Dr. Sravani Avula, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-730-5437 | |
Asif Zia Khattak, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3500 Gaston Ave, Dallas, TX 75246 Phone: 214-820-7604 | |
Sadia Malik, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-456-2533 Fax: 214-456-8130 | |
Sana Jamil Siddiqui, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-456-0488 Fax: 214-456-4486 |